[go: up one dir, main page]

ATE170749T1 - Verwendung von (-) cetirizin zur behandlung allergischer rhinitis und und asthma - Google Patents

Verwendung von (-) cetirizin zur behandlung allergischer rhinitis und und asthma

Info

Publication number
ATE170749T1
ATE170749T1 AT93921715T AT93921715T ATE170749T1 AT E170749 T1 ATE170749 T1 AT E170749T1 AT 93921715 T AT93921715 T AT 93921715T AT 93921715 T AT93921715 T AT 93921715T AT E170749 T1 ATE170749 T1 AT E170749T1
Authority
AT
Austria
Prior art keywords
cetirizine
treatment
allergic rhinitis
asthma
useful
Prior art date
Application number
AT93921715T
Other languages
English (en)
Inventor
Nancy M Gray
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25491375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE170749(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sepracor Inc filed Critical Sepracor Inc
Application granted granted Critical
Publication of ATE170749T1 publication Critical patent/ATE170749T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
AT93921715T 1992-09-24 1993-09-22 Verwendung von (-) cetirizin zur behandlung allergischer rhinitis und und asthma ATE170749T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95117992A 1992-09-24 1992-09-24

Publications (1)

Publication Number Publication Date
ATE170749T1 true ATE170749T1 (de) 1998-09-15

Family

ID=25491375

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93921715T ATE170749T1 (de) 1992-09-24 1993-09-22 Verwendung von (-) cetirizin zur behandlung allergischer rhinitis und und asthma

Country Status (12)

Country Link
US (1) US5698558A (de)
EP (2) EP0663828B1 (de)
JP (2) JPH08501561A (de)
AT (1) ATE170749T1 (de)
AU (2) AU4932093A (de)
CA (1) CA2145410A1 (de)
DE (2) DE10199031I2 (de)
DK (1) DK0663828T3 (de)
ES (1) ES2122042T3 (de)
LU (1) LU90898I2 (de)
NL (1) NL300085I2 (de)
WO (1) WO1994006429A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE170749T1 (de) * 1992-09-24 1998-09-15 Sepracor Inc Verwendung von (-) cetirizin zur behandlung allergischer rhinitis und und asthma
EP0885611A3 (de) * 1992-09-24 1999-01-07 Sepracor, Inc. Verfahren und Zusammensetzungen zur Behandlung von allergischen Krankheiten unter Verwendung von optisch reinen (+) Cetirizin
GB9305282D0 (en) * 1993-03-15 1993-05-05 Ucb Sa Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulphonyl)piperazine
US6469009B1 (en) 1996-04-08 2002-10-22 Ucb, S.A. Pharmaceutical compositions for the treatment of rhinitis
BE1011251A3 (fr) † 1997-07-03 1999-06-01 Ucb Sa Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
US6140337A (en) * 1997-12-23 2000-10-31 Schering Corporation Methods for the treatment of mental disorders
US6384038B1 (en) * 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
SE9802555D0 (sv) * 1998-07-16 1998-07-16 A & Science Invest Ab New pharmaceutical preparation and method
US6432961B1 (en) 1998-08-18 2002-08-13 Ucb S.A. Method for preventing the onset of asthma
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
AU2002256967A1 (en) * 2000-10-30 2002-09-12 Schering Corporation Treating or reducing the risk of cardiovascular disease
US7199241B1 (en) 2001-05-29 2007-04-03 Ucb, S.A. Process for preparing (S) and (R)-2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide
US6977301B1 (en) 2001-05-29 2005-12-20 Ucb, S.A. Process for preparing (S) and (R)—2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide
AU2003272450A1 (en) * 2002-09-13 2004-04-30 C. Steven Smith Novel composition and method for treatment of upper respiratory conditions
NZ540415A (en) * 2002-12-03 2008-06-30 Ucb Farchim Sa Use of levocetirizine for the treatment of persistent allergic rhinitis
AU2003228011A1 (en) * 2003-05-21 2004-12-13 Wockhardt Limited 2-(2-(4-((4-chlorophenyl) phenylmethyl)-1-piperazinyl)ethoxy)acetic acid monohydrochloride as anti-allergenic compound and process for its production
GB2403655A (en) * 2003-07-11 2005-01-12 Cipla Ltd Combined pharmaceutical product comprising a beta-2 adrenoreceptor agonist & an antihistamine for treatment of respiratory diseases such as asthma
WO2005041969A1 (en) * 2003-10-22 2005-05-12 Cipla Limited Pharmaceutical product comprising a beta-2 adrenergic agonist and an h1-receptor antagonist
WO2005077371A1 (en) * 2004-02-12 2005-08-25 Ucb Farchim Sa Use of levocetirizine for the preparation of a drug
EP1858866B1 (de) * 2005-03-03 2009-06-10 Ucb Farchim, S.A. Pyroglutamatsalze und deren verwendung bei der optischen trennung von zwischenprodukten für die synthese von dextrocetirizin und levocetirizin
US20090082364A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched levocedtirizine
JP5291324B2 (ja) * 2007-11-01 2013-09-18 沢井製薬株式会社 口腔内崩壊錠
ATE499352T1 (de) 2007-11-21 2011-03-15 Synthon Bv Verfahren zur herstellung von n- (diphenylmethyl)piperazinen
US7989623B2 (en) 2007-11-21 2011-08-02 Synthon Bv Process for making n-(diphenylmethyl)piperazines
US20100145049A1 (en) * 2008-11-21 2010-06-10 Jie Zhu Process for making n-(diphenylmethyl)piperazines
WO2010107404A1 (en) 2009-03-16 2010-09-23 Mahmut Bilgic Stable pharmaceutical combinations
US8569273B2 (en) 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
WO2010107689A1 (en) 2009-03-17 2010-09-23 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
TR201007652A2 (tr) 2010-09-20 2012-04-24 Bi̇lgi̇ç Mahmut Sinerjik etki.
TR201009398A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Fiziksel özellikleri geliştirilmiş tablet formülasyonları
KR20130009553A (ko) * 2011-07-15 2013-01-23 한미약품 주식회사 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제
KR102110304B1 (ko) 2017-06-30 2020-05-14 한미약품 주식회사 레보세티리진 및 몬테루카스트를 포함하는 안정성 및 복약순응도가 향상된 복합 츄어블정 및 그 제조방법
KR102885257B1 (ko) 2021-10-21 2025-11-12 한화제약주식회사 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 안정성이 개선된 필름코팅 정제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI75816C (fi) * 1981-02-06 1988-08-08 Ucb Sa Foerfarande foer framstaellning av terapeutiskt aktiv 2-/4-(difenylmetyl)-1-piperazinyl/-aettiksyror eller dess amid.
GB8827390D0 (en) * 1988-11-23 1988-12-29 Ucb Sa Process for preparation of 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-pipera-zinyl)ethoxy)-acetic acid & its dihydrochloride
GB8827391D0 (en) * 1988-11-23 1988-12-29 Ucb Sa Process for preparation of 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-pipera-zinyl)ethoxy)-acetic acid & its dihydrochloride
DE4209649C2 (de) * 1992-03-25 1998-12-24 Schloemann Siemag Ag Mehrstufiger hydraulischer Druck-Zylinder
EP0885611A3 (de) * 1992-09-24 1999-01-07 Sepracor, Inc. Verfahren und Zusammensetzungen zur Behandlung von allergischen Krankheiten unter Verwendung von optisch reinen (+) Cetirizin
ATE170749T1 (de) * 1992-09-24 1998-09-15 Sepracor Inc Verwendung von (-) cetirizin zur behandlung allergischer rhinitis und und asthma
GB9305282D0 (en) * 1993-03-15 1993-05-05 Ucb Sa Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulphonyl)piperazine

Also Published As

Publication number Publication date
EP0950412A2 (de) 1999-10-20
NL300085I1 (nl) 2002-05-01
JPH08501561A (ja) 1996-02-20
AU4932093A (en) 1994-04-12
DE10199031I2 (de) 2004-09-23
EP0663828B1 (de) 1998-09-09
DE69320975T2 (de) 1999-05-12
NL300085I2 (nl) 2002-06-03
DE10199031I1 (de) 2001-10-04
CA2145410A1 (en) 1994-03-31
ES2122042T3 (es) 1998-12-16
US5698558A (en) 1997-12-16
AU5934398A (en) 1998-05-21
LU90898I2 (en) 2002-04-08
JP2006036791A (ja) 2006-02-09
DE69320975D1 (de) 1998-10-15
WO1994006429A1 (en) 1994-03-31
AU711212B2 (en) 1999-10-07
DK0663828T3 (da) 1999-06-07
EP0663828A1 (de) 1995-07-26
EP0950412A3 (de) 2001-05-16

Similar Documents

Publication Publication Date Title
DE69320975D1 (de) Verwendung von (-) Cetirizin zur Behandlung allergischer Rhinitis und und Asthma
ATE177636T1 (de) Transdermale behandlung der nesselsucht mit optisch reinem (+)-cetirizin
AU2003273171A1 (en) Immunomodulatory compounds and methods of use thereof
ES2171543T3 (es) Composiciones administrables topicamente que contienen derivados del acido 3-benzoilfenilacetico para el tratamiento de trastornos inflamatorios oftalmicos.
DE69729125D1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
DK1049699T3 (da) Pyrazolotriaziner som CRF-antagonister
ATE430193T1 (de) Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
AU6995391A (en) Intermediates in the preparation of novel bicyclic esters and amides useful as specific 5-ht3 antagonists
DE69030632D1 (de) Substituierte Chinolincarboxylsäure
PT87294A (pt) Process for the preparation of 17beta-(cyclopropylamino)-androst-5-en-3beta-ol and related compounds useful as c17-20 lyase inhibitors and of pharmaceutical compositions containing the same
DE60129221D1 (de) Verwendung von alpha-msh und epo zur herstellung eines arzneimittels zur prophylaxe oder behandlung von durch ischämischen zuständen bewirkten krankheiten
ES2161211T3 (es) Broncodilatadores antimuscarinicos.
ATE269705T1 (de) Verwendung von optisch reinem (r)-tofizopam zur behandlung und pravention von angststörungen
DE68903907D1 (de) Cyclisches peptid, seine herstellung und seine verwendung zur behandlung von cardiovasculaeren stoerungen.
DK0548664T3 (da) 2,3,3a,4,5,9b-Hexahydro- 1H-benzo (e)indol-derivater
ES2138366T3 (es) Indol carbamatos como antagonistas de leucotrienos.
DE3484458D1 (de) Fluorphenoxy-derivate, herbizide zusammensetzungen und verfahren.
ATE283693T1 (de) Verwendung von pregabalin zur asthma behandlung
DE60213219D1 (de) Verwendung von thiolutin dioxide und ihren derivaten zur herstellung eines arzneimittels zur behandlung von zns-krankheiten
DK181985D0 (da) Triazolopyrimidinderivater
DE502004011353D1 (de) Verfahren zur Destillation eines Gemisches isomerer Diisocyanatodiphenylmethane
ATE441426T1 (de) Verwendung von angiotensinogen und deren analogen zur herstellung eines antiangiogenischen medikamentes